Drugs / Pentaglobin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03494959 | Dec 2019 → May 2024 overdue | infectious disease with sepsis | Italian Group for Bone Marrow Transplantation | Active not recruiting | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT04351724 | Apr 2020 → Dec 2021 | COVID-19 | Medical University of Vienna | Unknown | Met primary |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT03334006 Comparator | Nov 2017 → Sep 2027 expected | infectious disease with sepsis, peritonitis | RWTH Aachen University | Recruiting | No outcome recorded |
| Phase 2 | NCT02655133 Comparator | Jan 2016 → Jan 2018 | infectious disease with sepsis | Marche Polytechnic University | Completed | No outcome recorded |
| Phase 4 | NCT01006499 Comparator | Aug 2009 → Oct 2010 | neonatal sepsis | Zekai Tahir Burak Women's Health Research and Education Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pentaglobin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02655133 ↗ |
| Known as | IgGAM | “In addition, these biomarkers could help to guide a targeted, i.e. "personalized", adjuvant therapy with Pentaglobin® (IgGAM) in the indication of peritonitis.” NCT03334006 ↗ |
| Modality | Protein / enzyme biologic | “IgM enriched IVIG” NCT01006499 ↗ |
| Route | Intravenous | “Standard treatment plus 250 mg/Kg of Pentaglobin intravenously (given over 4 hours) daily for three days” NCT01006499 ↗ |